About-Face
The Worrisome 'Why' Behind Eli Lilly's Change of Heart
It's finally considering dropping its animal-health unit -- because it may have to.
This article is for subscribers only.
About its animal-health unit Elanco, Eli Lilly & Co. protested too much.
The drugmaker has repeatedly claimed Elanco was a core part of its business, rebuffing investor calls for a divestiture. But on Tuesday, along with its third-quarter earnings results, Lilly announced it will decide whether to spin off, sell, or keep the unit by mid-2018.